TapewireFind a company

person · Reporting owner

BRAENDER LORI J

Disclosed activity across 1 company

Tapewire entity
48292
SEC CIK
0001752955

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aquestive Therapeutics, Inc.

Report date May 07, 2026 · Filed May 11, 2026

Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect231,042 Reported balance After 2026-05-07 transaction · row 1
1 source row

Row 1 · 2026-05-07 · Tax withholding · Disposed 135,690 · Balance 231,042

F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 07, 2026 Filed May 11, 2026 20:35 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 135,690 $4.23 $573,968.70
Disclosure

SEC source: 0001214659-26-005932 · marketforms-73160.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,042

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
May 05, 2026 Filed May 7, 2026 21:31 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 76,147 $4.18 $318,294.46
Disclosure

SEC source: 0001214659-26-005747 · marketforms-73069.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,732

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Read SEC document
March 10, 2026 Filed Mar 11, 2026 16:52 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 SaleCommon Stock 40,102 $4.17 $167,345.65
Disclosure

SEC source: 0001214659-26-003145 · marketforms-72464.xml · nonDerivative · entry 2

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 442,879

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 16:52 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 50,000 $4.29 Strike: $4.29 $214,500.00
Disclosure

SEC source: 0001214659-26-003145 · marketforms-72464.xml · derivative · entry 3

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-03-09

F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 16:52 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 80,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-26-003145 · marketforms-72464.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 482,981

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 09, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 10,658 $2.65 $28,243.70
Disclosure

SEC source: 0001214659-25-004223 · marketforms-68569.xml · nonDerivative · entry 3

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 402,981

F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 60,000 $0.00 Strike: $2.65 $0.00
Disclosure

SEC source: 0001214659-25-004223 · marketforms-68569.xml · derivative · entry 4

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2035-03-07

F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 9,592 $2.65 $25,418.80
Disclosure

SEC source: 0001214659-25-004223 · marketforms-68569.xml · nonDerivative · entry 2

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 413,639

F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 110,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-25-004223 · marketforms-68569.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 423,231

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 07, 2025 Filed Apr 13, 2026 19:51 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantPerformance Stock Units · Derivative 82,500 $0.00 $0.00
Disclosure

SEC source: 0001214659-26-004592 · marketforms-72926.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2028-03-07

F1 · security: This Form 4 was filed late due to an inadvertent administrative oversight.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).

F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).

Read SEC document
March 09, 2024 Filed Mar 12, 2024 17:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 10,530 $4.88 $51,386.40
Disclosure

SEC source: 0001214659-24-004393 · marketforms-65147.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,231

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 14:36 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 67,500 $0.00 Strike: $5.68 $0.00
Disclosure

SEC source: 0001214659-24-004309 · marketforms-64690.xml · derivative · entry 2

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2034-03-07

F2 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 14:36 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 135,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-24-004309 · marketforms-64690.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 323,761

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
August 09, 2023 Filed Aug 9, 2023 20:30 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantPerformance Stock Units · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-23-010927 · marketforms-61884.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2026-05-05

F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Read SEC document
May 05, 2023 Filed May 5, 2023 20:00 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantPerformance Stock Units · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-23-006557 · marketforms-61237.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2026-05-05

F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Read SEC document
March 09, 2023 Filed Mar 9, 2023 20:06 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 150,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-23-003690 · marketforms-59525.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,761

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
November 04, 2022 Filed Nov 8, 2022 15:23 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 40,000 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001214659-22-013281 · marketforms-57371.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:26 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseWarrant (Right to Buy) · Derivative 13,761 $0.13 Strike: $0.96 $1,788.93
Disclosure

SEC source: 0001628280-22-016871 · wf-form4_165489634971386.xml · derivative · entry 2

BRAENDER LORI J · CIK 0001752955 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,761

Underlying: Common Stock · 13,761 shares

Expires 2027-06-08

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:26 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 13,761 $0.96 $13,210.56
Disclosure

SEC source: 0001628280-22-016871 · wf-form4_165489634971386.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,761

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 15:25 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 160,000 $0.00 Strike: $2.55 $0.00
Disclosure

SEC source: 0001214659-22-003896 · marketforms-55762.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 11, 2021 Filed Mar 15, 2021 21:10 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 75,000 $0.00 Strike: $5.30 $0.00
Disclosure

SEC source: 0001214659-21-003151 · marketforms-51879.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 20:45 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 60,000 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001214659-20-002747 · marketforms-48350.xml · derivative · entry 2

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-03-16

F2 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 20:45 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 14,000 $1.54 $21,624.40
Disclosure

SEC source: 0001214659-20-002747 · marketforms-48350.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: This transaction was executed in multiple transactions with prices ranging from $1.46 to $1.65. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 09, 2019 Filed Aug 13, 2019 20:30 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 10,000 $4.07 $40,747.00
Disclosure

SEC source: 0001214659-19-005183 · marketforms-45477.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

F1 · price: This transaction was executed in multiple transactions with prices ranging from $4.03 to $4.08. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 28, 2019 Filed Mar 4, 2019 21:50 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 100,000 $0.00 Strike: $8.05 $0.00
Disclosure

SEC source: 0001214659-19-001753 · marketforms-44353.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-02-28

F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.

Read SEC document
November 27, 2018 Filed Nov 29, 2018 21:01 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 1,000 $10.57 $10,570.00
Disclosure

SEC source: 0001140361-18-044032 · form4.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Read SEC document
September 10, 2018 Filed Sep 13, 2018 21:43 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantStock Option (Right to Purchase) · Derivative 85,000 $0.00 Strike: $18.67 $0.00
Disclosure

SEC source: 0001140361-18-038414 · form4.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2028-09-10

F1 · derivative.exercise_date: The shares underlying the options vest in three annual installments of 25%, 25% and 50% on September 10, 2019, September 10, 2020 and September 10, 2021, respectively, subject in each case to Ms. Braender's continuous service with the Issuer from the grant date through the applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.